Outcomes of COVID-19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders
Allergy
.
2023 Jan;78(1):301-304.
doi: 10.1111/all.15476.
Epub 2022 Aug 23.
Authors
Matthew P Giannetti
1
2
,
Francesco Olivieri
3
,
Grace Godwin
1
,
Emma Weller
1
,
Jennifer Nicoloro-SantaBarbara
2
4
,
Patrizia Bonadonna
3
,
Roberta Zanotti
5
,
Giovanna Zanoni
6
,
Karin Hartmann
7
8
,
Mariana Castells
1
2
Affiliations
1
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
2
Harvard Medical School, Boston, Massachusetts, USA.
3
Allergy Unit, Verona University Hospital, Verona, Italy.
4
Department of Psychiatry, Brigham and Women's, Boston, Massachusetts, USA.
5
Department of Medicine, Section of Hematology, Verona, Italy.
6
Immunology Unit, Verona University Hospital, Verona, Italy.
7
Division of Allergy, University Hospital Basel and University of Basel, Basel, Switzerland.
8
Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
PMID:
35962620
PMCID:
PMC9538600
DOI:
10.1111/all.15476
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Mast Cell Activation Syndrome*
Mast Cells
Mastocytosis*
Vaccination
Substances
COVID-19 Vaccines